Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ventus Therapeutics U S Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are being handled by 1 distinct examiner, ARCORIA, PAUL JOSEPH, within 1 distinct art unit. This concentration of the company's active docket under a single examiner and art unit indicates a centralized prosecution environment.
ARCORIA, PAUL JOSEPH is the busiest examiner for the portfolio, holding 2 pending office actions. Since he is the only examiner with active matters for the company, he is the sole official responsible for the current prosecution of their pending intellectual property. This arrangement allows the company to maintain a singular focus and consistent communication style throughout its current USPTO interactions.
The presence of 2 pending office actions with 1 examiner in 1 distinct art unit suggests that the company's technology is being evaluated within a specific technical niche. Practitioners can focus their resources on addressing the specific preferences and requirements of ARCORIA, PAUL JOSEPH. This structure simplifies the management of the company's patent docket and allows for a unified strategy within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARCORIA, PAUL JOSEPH | 2 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706884 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ARCORIA, PAUL JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706884 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ARCORIA, PAUL JOSEPH | 1621 | §102§103§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18544945 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | ARCORIA, PAUL JOSEPH | 1621 | §103DP | Non-Final OA | — | Pending | Dec 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial